Bobby Shayegan1, Christopher J D Wallis2, Robert J Hamilton3, Scott C Morgan4, Ilinas Cagiannos4, Naveen S Basappa5, Cristiano Ferrario6, Geoffrey T Gotto7, Ricardo Fernandes8, Soumyajit Roy9, Krista L Noonan10, Tamim Niazi11, Sebastien J Hotte12, Fred Saad13, Huong Hew14, Laura Park-Wyllie14, Katherine F Y Chan14, Shawn Malone4. 1. St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada. 2. Mount Sinai Hospital, Toronto, ON, Canada. wallis.cjd@gmail.com. 3. Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. 4. The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada. 5. Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 6. Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada. 7. Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada. 8. London Regional Cancer Program, London, ON, Canada. 9. Radiation Oncology, Rush University Cancer Center, Chicago, IL, USA. 10. BC Cancer Agency, University of British Columbia, Surrey, BC, Canada. 11. Jewish General Hospital, McGill University, Montreal, QC, Canada. 12. Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada. 13. Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada. 14. Janssen Inc., Toronto, ON, Canada.
Abstract
BACKGROUND: The adoption of docetaxel for systemic treatment of metastatic prostate cancer (PCa), in both castration-sensitive (mCSPC) and castration-resistant (mCRPC) settings, is poorly understood. This study examined the real-world utilization of docetaxel in these patients and their outcomes. METHODS: A retrospective population-based study used administrative data from Ontario, Canada, to identify men aged ≥66 years who were diagnosed with de novo mCSPC or mCRPC between 2014 and 2019 and received docetaxel. The study assessed treatment tolerability and toxicity, and survival in both cohorts. Descriptive and comparative statistical analysis were conducted. RESULTS: The study identified 11.2% (399/3556) and 13.2% (203/1534) patients diagnosed with de novo mCSPC and with mCRPC who received docetaxel respectively. The median age in both cohorts was 72 years (IQR: 68-76). Overall, 43.9% (n = 175) patients with de novo mCSPC and 52.1% (n = 85) with mCRPC completed ≥6 cycles of docetaxel. Over two-fifth also needed dose adjustments in both cohorts. Hospitalization or emergency department visit for febrile neutropenia were noted in 15.8% (n = 63) of de novo mCSPC patients and similarly in 19% (n = 31) of mCRPC cohort. The median survival of PCa patients who completed ≥6 cycles of docetaxel was significantly longer relative to those who completed <4 cycles: 32.7 vs. 23.5 months (p < 0.001) for mCSPC and 20.5 vs. 10.7 (p = 0.012) for mCRPC respectively. CONCLUSIONS: In this population-based study of elderly patients with metastatic PCa, treatment with docetaxel was associated with poor tolerability and higher toxicity compared with clinical trials. Receipt of limited cycles and reduced overall dose of docetaxel were associated with inferior overall survival.
BACKGROUND: The adoption of docetaxel for systemic treatment of metastatic prostate cancer (PCa), in both castration-sensitive (mCSPC) and castration-resistant (mCRPC) settings, is poorly understood. This study examined the real-world utilization of docetaxel in these patients and their outcomes. METHODS: A retrospective population-based study used administrative data from Ontario, Canada, to identify men aged ≥66 years who were diagnosed with de novo mCSPC or mCRPC between 2014 and 2019 and received docetaxel. The study assessed treatment tolerability and toxicity, and survival in both cohorts. Descriptive and comparative statistical analysis were conducted. RESULTS: The study identified 11.2% (399/3556) and 13.2% (203/1534) patients diagnosed with de novo mCSPC and with mCRPC who received docetaxel respectively. The median age in both cohorts was 72 years (IQR: 68-76). Overall, 43.9% (n = 175) patients with de novo mCSPC and 52.1% (n = 85) with mCRPC completed ≥6 cycles of docetaxel. Over two-fifth also needed dose adjustments in both cohorts. Hospitalization or emergency department visit for febrile neutropenia were noted in 15.8% (n = 63) of de novo mCSPC patients and similarly in 19% (n = 31) of mCRPC cohort. The median survival of PCa patients who completed ≥6 cycles of docetaxel was significantly longer relative to those who completed <4 cycles: 32.7 vs. 23.5 months (p < 0.001) for mCSPC and 20.5 vs. 10.7 (p = 0.012) for mCRPC respectively. CONCLUSIONS: In this population-based study of elderly patients with metastatic PCa, treatment with docetaxel was associated with poor tolerability and higher toxicity compared with clinical trials. Receipt of limited cycles and reduced overall dose of docetaxel were associated with inferior overall survival.
Authors: Alan I So; Kim N Chi; Brita Danielson; Neil E Fleshner; Anil Kapoor; Tamim Niazi; Frederic Pouliot; Ricardo A Rendon; Bobby Shayegan; Srikala Sridhar; Eric Vigneault; Fred Saad Journal: Can Urol Assoc J Date: 2019-12-05 Impact factor: 1.862
Authors: Manuel Caitano Maia; Allan A Lima Pereira; Liana Valente Lage; Natalia Moreno Fraile; Victor Van Vaisberg; Guilherme Kudo; Romualdo Barroso-Sousa; Diogo Assed Bastos; Carlos Dzik Journal: J Glob Oncol Date: 2017-03-27
Authors: Igor Tsaur; Anita Thomas; Michelle Monecke; Marion Zugelder; Jochen Rutz; Timothy Grein; Sebastian Maxeiner; Hui Xie; Felix K-H Chun; Florian Rothweiler; Jindrich Cinatl; Martin Michaelis; Axel Haferkamp; Roman A Blaheta Journal: Cancers (Basel) Date: 2022-06-24 Impact factor: 6.575